THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATOR

INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU

MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION

IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers.

breakthrough approach for treatment of autoimmune and inflammatory diseases

16 September, 2019 - Tiziana Life Sciences plc (NASDAQ:TLSA and AIM: TILS), a clinical stage biotechnology company focused

on developing targeted drugs for cancer and inflammatory diseases, is pleased to announce (further to the announcement made on

1 May 2019) that the U.S. Food and Drug Administration (FDA) has allowed the initiation of a Phase I clinical trial in healthy

volunteers using a novel oral enteric-coated capsule formulation of Foralumab, a fully human monoclonal antibody (mAb), in collaboration

with the Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA. This is the first clinical trial in which

Foralumab will be administered orally to healthy subjects. Our objective is to develop orally administered Foralumab for treatment

of autoimmune and inflammatory diseases.

scientific rationale for this approach was originally discovered by Dr. Howard Weiner, professor at the Brigham and Women's

Hospital, Harvard Medical School. Dr. Weiner discovered that oral or nasal administration of anti-CD3 mAb induces mucosal tolerance

to upregulate T regulatory cells (Tregs) capable of providing site-targeted immunomodulation to suppress inflammation. Therefore,

this scientific concept could be effective for the treatment of a variety of autoimmune and inflammatory diseases1-5.

therapeutic approach of oral administration with Foralumab should greatly enhance our ability to treat neurodegenerative and inflammatory

diseases. We have also explored the nasal administration of Foralumab for the treatment of progressive MS. We believe nasal and

oral administration with Foralumab opens innovative avenues to treat inflammatory and autoimmune diseases by inducing different

classes of Tregs. Thus, mucosal activation stimulating Tregs is a physiological mechanism which we think might be safer than other

treatment approaches," commented Dr. Weiner.

L. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple

Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston.

He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's

disease, amyotrophic lateral sclerosis, stroke and brain tumours. He has also pioneered the investigation of the mucosal immune

system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment

Harvard Medical Centre

and Women's Hospital (BWH, "The Brigham") is located adjacent to Harvard Medical School, of which it is the second largest

teaching affiliate. It is the largest hospital of the Longwood Medical and Academic Area in Boston, Massachusetts, USA.

With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare, the largest healthcare provider

in Massachusetts. Brigham and Women's Hospital conducts the second largest hospital-based research program in the world, with

an annual research budget of more than $630 million. Pioneering milestones include the world's first successful heart valve

operation and the world's first solid organ transplant.

Autoimmune Diseases and Foralumab

diseases constitute a major medical problem and include diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis

and inflammatory bowel disease. Other diseases, that have inflammatory components include diseases such as NASH, atherosclerosis

and stroke. The induction of regulatory cells at mucosal surfaces by the oral or nasal administration of antigens has been shown

to treat a large variety of autoimmune and inflammatory diseases in animal models with minimal toxicity. Foralumab was developed

by Novimmune and has been acquired by Tiziana Life Sciences PLC. Foralumab (formerly NI-0401) is thus far the only entirely human

anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases

in the classic side effects of cytokine release syndrome (CRS) and improves the overall safety profile of foralumab.

a humanized mouse model (NOD/SCID IL2 c-/-) developed in Dr Kevan Herold's laboratory, it was show that while targeting

the T cell receptor, orally administered foralumab modulates immune responses of the T cells, enhances regulatory T cells and

thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse

events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration

of foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction

of regulatory T cells.

Tiziana Life Sciences

Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to

treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases.

Foralumab is the only fully human anti-CD3 monoclonal antibody known to the company in clinical development in the world. This

compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis

(NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease

(IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts

but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs;

and assumptions. Words such as anticipates,' expects,' intends,' plans,' believes,'

'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These

statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors,

some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially

from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security

holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the

date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which

the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking

statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required

by law or by any appropriate regulatory authority

more information go to http://www.tizianalifesciences.com

announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

news and updates from Tiziana Life Sciences plc by signing up to get email alerts straight to you on https://ir.tizianalifesciences.com